Jazz Pharmaceuticals plc — Director's Dealing 2022

Jul 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-07-05

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-05	Ordinary Shares	M	9700	$46.83	Acquired	360687	Direct
2022-07-05	Ordinary Shares	S	5839	$156.6513	Disposed	354848	Direct
2022-07-05	Ordinary Shares	S	436	$157.1306	Disposed	354412	Direct
2022-07-05	Ordinary Shares	S	1000	$156.95	Disposed	353412	Direct
2022-07-05	Ordinary Shares	S	1500	$160.0	Disposed	351912	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-05	Non-Qualified Stock Option (right to buy)	$46.83	M	9700	Disposed	2022-08-08	Ordinary Shares (9700)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.05 to $157.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $157.05 to $157.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.